Prognosis

• Median time to progression of asymptomatic WM ~7 years.

• Median survival of patients with WM ~5 years; patients who achieve CR with chlorambucil have median survival of ~11 years.

• Up to 20% die of unrelated causes and 33% from infection; others from disease progression, transformation and bleeding.

• Indolent course may be interrupted by transformation into aggressive high grade NHL which is often poorly responsive to treatment; poor tolerance of aggressive treatment due to poor marrow reserve.

Gertz, M.A. et al. (2003) Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol, 30, 121-126; Kyle, R.A. et al. (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol, 30, 116-120; Weber, D. et al. (2003) Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol, 30, 127-131.

0 0

Post a comment